In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA clearance with its treatment for ...

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

A bipartisan group of 39 state attorneys general is calling on congressional leadership to pass a bill that would prohibit ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target autoimmune diseases via B cell depletion.

Merck licenses Cyprumed's oral drug delivery platform in $493M deal to develop oral peptide formulations, potentially for GLP-1 drugs.

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

Johnson & Johnson is maintaining its 2025 financial guidance and raising its sales forecast despite President Donald Trump’s efforts to tariff pharmaceuticals.